MedPath
FDA Approval

Ibandronate sodium

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 30, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ibandronate(150 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Dr. Reddy's Laboratories Limited - FTO III

Dr. Reddy's Laboratories Limited

918608162

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ibandronate sodium

Product Details

NDC Product Code
55111-575
Application Number
ANDA078997
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
April 30, 2023
Code: J12U072QL0Class: ACTIMQuantity: 150 mg in 1 1
Silicon DioxideInactive
Code: ETJ7Z6XBU4Class: IACT
croscarmellose sodiumInactive
Code: M28OL1HH48Class: IACT
lactose monohydrateInactive
Code: EWQ57Q8I5XClass: IACT
CROSPOVIDONEInactive
Code: 2S7830E561Class: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
sodium stearyl fumarateInactive
Code: 7CV7WJK4UIClass: IACT
POVIDONEInactive
Code: FZ989GH94EClass: IACT
HYPROMELLOSESInactive
Code: 3NXW29V3WOClass: IACT
titanium dioxideInactive
Code: 15FIX9V2JPClass: IACT
polyethylene glycol 400Inactive
Code: B697894SGQClass: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3Class: IACT
AMMONIAInactive
Code: 5138Q19F1XClass: IACT
FERROSOFERRIC OXIDEInactive
Code: XM0M87F357Class: IACT
shellacInactive
Code: 46N107B71OClass: IACT
© Copyright 2025. All Rights Reserved by MedPath